Merck & Co., Inc. is looking to bring a new vaccine to market for the prevention of pneumococcal disease in adults, but the company will have to compete against Pfizer Inc., which has long been a rival in the market with its blockbuster Prevnar franchise. The company hopes the new vaccine could offer the broadest protection for adults.
Merck & Co. Hits Target With Pneumococcal Vaccine, As Rivalry With Pfizer Continues
The vaccine, V116, targets eight unique serotypes, and it is particularly geared toward preventing pneumococcal disease in adults, especially the elderly, according to Merck.
